Special attention is required when pharmacological treatment is indicated for a pregnant woman. P-glycoprotein (MDR1) is a well-known transporter localized in the maternal blood-facing apical membrane of placental syncytiotrophoblast and is considered to play an important role in protecting the developing fetus. Maraviroc, a MDR1 substrate that is registered for treatment of HIV infection, shows a low toxicity profile, suggesting favorable tolerability also if administered to pregnant women. Nevertheless, there is only poor understanding to date regarding the extent to which it permeates across the placental barrier and what are the transport mechanisms involved. Endeavoring to clarify the passage of maraviroc across placenta, we used in this study the method of closed-circuit perfusion of maraviroc across human placental cotyledon. The data obtained confirmed slight involvement of MDR1, but they also suggest possible interaction with other transport system(s) working in the opposite direction from that of MDR1. Complementary in vitro studies, including cellular experiments on choriocarcinoma BeWo cells as well as transporter-overexpressing MDCKII and A431 cell lines and accumulation in placental fresh villous fragments, revealed maraviroc transport by MRP1, OATP1A2, and OATP1B3 transporters. Based on mRNA expression data in the placental tissue, isolated trophoblasts, and fetal endothelial cells, especially MRP1 and OATP1A2 seem to play a crucial role in cooperatively driving maraviroc into placental tissue. By the example of maraviroc, we show here the important interplay of transporters in placental drug handling and its possibility to overcome the MDR1-mediated efflux.

Charles University Faculty of Pharmacy in Hradec Kralove Department of Analytical Chemistry Akademika Heyrovskeho 1203 Hradec Kralove Czech Republic

Charles University Faculty of Pharmacy in Hradec Kralove Department of Pharmacology and Toxicology Akademika Heyrovskeho 1203 Hradec Kralove Czech Republic

Medical University of Graz Department of Obstetrics and Gynecology 8036 Graz Austria

Membrane Protein Research Group Institute of Enzymology Research Centre for Natural Sciences Magyar tudósok krt 2 H 1117 Budapest Hungary

000      

00000naa a2200000 a 4500

001      

bmc21012175

003      

CZ-PrNML

005      

20210507101629.0

007      

ta

008      

210420s2020 fr f 000 0|eng||

009      

AR

024    7_

$a 10.1016/j.biopha.2020.110506 $2 doi

035    __

$a (PubMed)32768979

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a fr

100    1_

$a Tupova, Lenka $u Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Pharmacology and Toxicology, Akademika Heyrovskeho 1203, Hradec Kralove, Czech Republic

245    10

$a Interplay of drug transporters P-glycoprotein (MDR1), MRP1, OATP1A2 and OATP1B3 in passage of maraviroc across human placenta / $c L. Tupova, B. Hirschmugl, S. Sucha, V. Pilarova, V. Székely, É. Bakos, L. Novakova, C. Özvegy-Laczka, C. Wadsack, M. Ceckova

520    9_

$a Special attention is required when pharmacological treatment is indicated for a pregnant woman. P-glycoprotein (MDR1) is a well-known transporter localized in the maternal blood-facing apical membrane of placental syncytiotrophoblast and is considered to play an important role in protecting the developing fetus. Maraviroc, a MDR1 substrate that is registered for treatment of HIV infection, shows a low toxicity profile, suggesting favorable tolerability also if administered to pregnant women. Nevertheless, there is only poor understanding to date regarding the extent to which it permeates across the placental barrier and what are the transport mechanisms involved. Endeavoring to clarify the passage of maraviroc across placenta, we used in this study the method of closed-circuit perfusion of maraviroc across human placental cotyledon. The data obtained confirmed slight involvement of MDR1, but they also suggest possible interaction with other transport system(s) working in the opposite direction from that of MDR1. Complementary in vitro studies, including cellular experiments on choriocarcinoma BeWo cells as well as transporter-overexpressing MDCKII and A431 cell lines and accumulation in placental fresh villous fragments, revealed maraviroc transport by MRP1, OATP1A2, and OATP1B3 transporters. Based on mRNA expression data in the placental tissue, isolated trophoblasts, and fetal endothelial cells, especially MRP1 and OATP1A2 seem to play a crucial role in cooperatively driving maraviroc into placental tissue. By the example of maraviroc, we show here the important interplay of transporters in placental drug handling and its possibility to overcome the MDR1-mediated efflux.

650    _2

$a P-glykoproteiny $x antagonisté a inhibitory $x genetika $x metabolismus $7 D018435

650    _2

$a akridiny $x farmakologie $7 D000166

650    _2

$a zvířata $7 D000818

650    _2

$a látky proti HIV $x krev $x metabolismus $x farmakologie $7 D019380

650    _2

$a nádorové buněčné linie $7 D045744

650    _2

$a psi $7 D004285

650    _2

$a lékové interakce $7 D004347

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a regulace genové exprese $7 D005786

650    _2

$a lidé $7 D006801

650    _2

$a buňky MDCK $7 D061985

650    _2

$a maravirok $x krev $x metabolismus $7 D000077592

650    _2

$a proteiny spojené s mnohočetnou rezistencí k lékům $x genetika $x metabolismus $7 D027425

650    _2

$a přenašeče organických aniontů $x antagonisté a inhibitory $x genetika $x metabolismus $7 D027361

650    _2

$a perfuze $7 D010477

650    _2

$a placenta $x účinky léků $x metabolismus $7 D010920

650    _2

$a placentární oběh $7 D021041

650    _2

$a těhotenství $7 D011247

650    _2

$a ritonavir $x farmakologie $7 D019438

650    _2

$a protein OATP1B3 $x antagonisté a inhibitory $x genetika $x metabolismus $7 D000074542

650    _2

$a tetrahydroisochinoliny $x farmakologie $7 D044005

655    _2

$a časopisecké články $7 D016428

700    1_

$a Hirschmugl, Birgit $u Medical University of Graz, Department of Obstetrics and Gynecology, 8036, Graz, Austria

700    1_

$a Sucha, Simona $u Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Pharmacology and Toxicology, Akademika Heyrovskeho 1203, Hradec Kralove, Czech Republic

700    1_

$a Pilarova, Veronika $u Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Analytical Chemistry, Akademika Heyrovskeho 1203, Hradec Kralove, Czech Republic

700    1_

$a Székely, Virág $u Membrane Protein Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Magyar tudósok krt. 2., H-1117, Budapest, Hungary

700    1_

$a Bakos, Éva $u Membrane Protein Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Magyar tudósok krt. 2., H-1117, Budapest, Hungary

700    1_

$a Novakova, Lucie $u Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Analytical Chemistry, Akademika Heyrovskeho 1203, Hradec Kralove, Czech Republic

700    1_

$a Özvegy-Laczka, Csilla $u Membrane Protein Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Magyar tudósok krt. 2., H-1117, Budapest, Hungary

700    1_

$a Wadsack, Christian $u Medical University of Graz, Department of Obstetrics and Gynecology, 8036, Graz, Austria

700    1_

$a Ceckova, Martina $u Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Pharmacology and Toxicology, Akademika Heyrovskeho 1203, Hradec Kralove, Czech Republic. Electronic address: martina.ceckova@faf.cuni.cz

773    0_

$w MED00005486 $t Biomedicine & pharmacotherapy Biomedecine & pharmacotherapie $x 1950-6007 $g Roč. 129, č. - (2020), s. 110506

856    41

$u https://pubmed.ncbi.nlm.nih.gov/32768979 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20210420 $b ABA008

991    __

$a 20210507101629 $b ABA008

999    __

$a ok $b bmc $g 1650531 $s 1132554

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2020 $b 129 $c - $d 110506 $e 20200712 $i 1950-6007 $m Biomedicine & pharmacotherapy $n Biomed Pharmacother $x MED00005486

LZP    __

$a Pubmed-20210420